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Abstract
Background: The exact mechanism of the protective role of Resveratrol (Res) in lipid metabolism and oxidative
stress is not well elucidated. The present study aimed to investigate the potential benefits and possible
mechanisms of Res on the amelioration of oxidative stress and hepatic steatosis in a KKAy mouse model.
Methods: A total of 30 KKAy male mice were randomly divided into three groups: a normal chow group, a low
resveratrol group and a high resveratrol group. After a 12-wk study period, serum levels of TG, TC, LDL-C and
HDL-C, the liver content of TG and TC, ROS, GSH, GPx, SOD and MDA levels were measured. Ectopic lipid deposition
was observed in sectioned frozen liver tissues. The mRNA levels of ATGL and HSL in the liver tissues were
determined via real-time PCR. Furthermore, the protein expression of p47phox, gp91phox, ATGL, HSL, Sirt1,
AMPK and FOXO1 were analyzed using western blotting.
Results: Following Res supplementation, serum levels of TG and MDA were decreased, while the HDL-C and
SOD levels were increased in KKAy mice. Furthermore, Res treatment increased GSH and GPx in liver tissues,
while it decreased ROS. In addition, Res significantly reduced hepatic steatosis. After Res treatment, concentrations
of p47phox (membrane) and gp91phox proteins were reduced, while p-HSL, HSL and ATGL protein expression
levels were increased. Mechanistically, the levels of Sirt1, p-AMPK and p-FOXO1 expression in the liver tissues
were up-regulated following supplementation with Res, and FOXO1 protein was released from the nucleus
into the cytoplasm.
Conclusions: Res is able to attenuate hepatic steatosis and lipid metabolic disorder and enhance the
antioxidant ability in KKAy mice, possibly by up-regulating Sirt1 expression and the phosphorylation of AMPK.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) affects up to
15 to 20% of the general population and is the most com-
mon cause of chronic liver disease. NAFLD includes a var-
iety of histological conditions ranging from simple steatosis
to non-alcoholic steatohepatitis (NASH), liver fibrosis, cir-
rhosis, and hepatocellular carcinoma [1]. Although NAFLD
is known to be correlated with many etiological factors,
i t sp a t h o g e n e s i sr e m a i n sp o o r l yu n d e r s t o o d .T h em o s t
common risk factors are obesity, insulin resistance,
dyslipidemia, and genetic susceptibility, which affect hep-
atic triglyceride homeostasis [2]. Previous studies have
confirmed that hepatic steatosis mostly results from the
increased free fatty acid (FFA) supply due to increased
lipolysis and/or increased intake of dietary fat, which con-
tributes to 60% of hepatic fat content [3]. Hormone-
sensitive lipase (HSL) and adipose triglyceride lipase
(ATGL), two enzymes critical for lipolysis in adipose
tissues, have been found to play an important role in
hepatic lipid homeostasis [4]. Dysfunctional lipolysis
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pathogenesis of hepatic steatosis. Triglyceride accumula-
tion in patients with NASH may eventually lead to the de-
velopment of cirrhosis. However, to date, there are no
therapies proven effective in halting NAFLD progression.
Hence, it is of great clinical value to further understand
the mechanisms underlying the progression of NAFLD
and to identify novel therapeutic targets.
Resveratrol (Res) is known as a natural polyphenol,
which is synthesized by plants and is present in the skins
of grapes, nuts, and, in the highest concentration, red
wine [5]. Previous studies have shown that Res may be a
cardioprotective, cancer chemopreventive and chemo-
therapeutic agent [6]. Recently, Res has gained attention
for its protection against metabolic disease. Baur JA
et al. reported that Res improved health and survival in
mice fed a high-calorie diet [7]. Additionally, Res can de-
crease liver lesions induced by alcohol and hepatotoxic
drugs [8]. Due to its beneficial effects on energy metab-
olism, Res is suggested to be a promising new thera-
peutic approach for treating metabolic diseases.
Sirt1, an NAD-dependent deacetylase, is a key protein
involved in many of the effects of Res. An in vitro study
showed that Res, a Sirt1 activator, enhanced insulin sen-
sitivity in a Sirt1-dependent manner and attenuated high-
fat-diet-induced insulin resistance [9]. The cellular energy
sensor, AMP-activated protein kinase (AMPK) has been
demonstrated to be closely related to insulin resistance
and hepatic steatosis, which could be of great relevance
for the treatment of metabolic syndrome [10]. Recent
studies have shown that AMPK activation increased
the fatty aid oxidation of skeletal muscle in rats [11].
Additionally, AMPK is reported to regulate metabol-
ism by modulating Sirt1 activity [12]. Additional studies
have shown that the tumor suppressor LKB1 kinase could
activate AMPK and regulate apoptosis in response to en-
ergy stress via the Sirt1 pathway [13].
The KKAy mouse was originally developed by crossing
the KK mouse with the yellow obese mouse (Ay mouse),
which are obese, hyperglycemic, hyperinsulinemic, and
insulin resistant, therefore applied as animal model for the
research on obesity or metabolic disorders [14]. The
C57BL/6 J mice were chosen as the control group. So far,
whether the metabolic protective effect of Res also occurs
in KKAy mice remains unclear. Moreover, the exact
mechanism of the protective role of Res is not elucidated
and is the focus of our study. In a previous study, we dis-
covered that Res could improve insulin sensitivity and
ameliorate insulin resistance in KKAy mice, which may be
associated with the up-regulation of Sirt1 protein in the
liver and soleus muscles and, consequently, Sirt1 and
AMPK activation [15]. In this study, we wanted to investi-
gate the effect and mechanism of Res on the regulation of
oxidative activation and lipid metabolism.
Materials and methods
Materials
Resveratrol was purchased from Yixin Pharm, Inc. (Zhejiang,
China); The triglyceride (TG) kit, total cholesterol (TC)
kit, low density lipoprotein cholesterol (LDL-C) kit, high
density lipoprotein cholesterol (HDL-C) kit, superoxide
dismutase (SOD) kit, malonaldehyde (MDA) kit, free fatty
acid (FFA) kit, reactive oxygen species (ROS) kit, gluta-
thione (GSH) kit, glutathione peroxidase (GPx) kit, and
the coomassie brilliant blue kit were purchased from
Jiancheng Bioengineering Institute (Nanjing, China); rabbit
anti-mouse p47phox polyclonal antibody was purchased
from LifeSpan Biosciences, Inc. (WA, USA); rabbit anti-
mouse Sirt1 monoclonal antibody and the gp91phox
polyclonal antibody were procured from Abcam, Inc.
(Cambridge, UK); Adipose triglyceride lipase (ATGL),
hormone-sensitive lipase (HSL), and p-HSL (Ser660)
antibodies were purchased from Santa Cruz Biotech
(Texas, USA); the primary antibodies including rabbit
anti-mouse AMPK, p-AMPK (Thr172), FOXO1, and p-
FOXO1 (Thr24) were purchased from Cell Signaling
Technology (MA, USA); GAPDH antibody was obtained
from Boster, Inc. (Wuhan, China); the BCA kit and HRP-
labeled goat anti-rabbit secondary antibody were from
Beyotime, Inc. (Jiangsu, China).
Experimental animals
A total of 30 8-week-old KKAy male mice were obtained
from Jackson Laboratory (Bar Harbor, ME). A total of 10
8-week-old C57BL/6 J male mice from the Animal
Experimental Center of Guangdong Province (Guangdong,
China) were chosen as the control group. All mice were
maintained in a temperature- and humidity-controlled en-
vironment with a 12-h light/dark cycle and fed a standard
laboratory chow for a 1-wk acclimation period. Subse-
q u e n t l y ,t h eK K A ym a l em i c ew e r er a n d o m l yd i v i d e di n t o
3 intervention groups based on body weight: a standard
chow intake group (KKAy group), a low resveratrol group
(KKAy+Low Res) and a high resveratrol group (KKAy+
High Res). The control and KKAy groups were fed a stand-
ard AIN93G diet, while the Low Res and High Res groups
were fed a standard AIN93G diet supplemented with
Res at doses of 2 and 4 g/kg diet, respectively. The dos-
ages of Res treatment were referred to the previous
publication [16]. Blood samples of mice were drawn
from the orbital veins for blood lipid measuring before
the experimental intervention. All animals were allowed
free access to food and water throughout the study.
Body weight (BW) and food intake were measured weekly.
After a 12-wk study period, mice of all groups were sacri-
ficed under anesthesia after fasting for 12 h. Serum
samples were collected and stored at −80°C prior to
use. The liver tissues were removed, weighed and also
stored at −80°C prior to use. This study was approved
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Serum analyses
Serum levels of TG, TC, LDL-C and HDL-C were quan-
tified using commercial enzyme-linked immunosorb-
ent assay (ELISA) kits according to the manufacturer’s
instructions.
Liver tissue analyses
The hepatic index was obtained by dividing the wet liver
weight by rat weight and multiplying by 100. Fresh liver
tissue samples of 500 mg each were prepared, ground
down in 0.5 mL saline solution, extracted with a mixture
of chloroform and methanol, and then stored overnight
at 4°C after vibration. The liver tissue homogenates were
centrifuged at 3500 rpm for 20 min the next day. Next,
the lower-phase liquid was collected to measure the TG
and TC contents using specific kits according to the man-
ufacturer’s instructions.
Measurement of SOD, MDA, FFA, ROS, GSH, and GPx
levels
The serum FFA, SOD and MDA contents were detected
according to the manufacturer’s instructions. Further-
more, prepared fresh liver tissue samples were ground
down in saline solution to make 10% liver tissue homog-
enates, followed by centrifuging at 3500 rpm for 20 min.
Next, the supernatant was collected to measure the con-
tents of SOD, MDA, ROS, GSH, and GPx using specific
kits according to the manufacturer’s instructions. ROS
measurement was referred to the previous described
protocol [17].
Frozen liver sections
In brief, fresh liver tissues were embedded in OCT buf-
fer and frozen in liquid nitrogen. The frozen specimens
were sectioned into 4 μm sections then stained with Oil
Red O. The slides were then mounted with neutral gum
and observed and photographed under the microscope.
Real-time PCR analysis
The mRNA was extracted from the liver tissues using
trizol and was used to synthesize cDNA. Specifically,
1 μL of 1 g/L RNA was mixed with 4 μL of 5 ×Prime
Script buffer, 1 μL RT enzyme mix I, 1 μL of oligo dT
primer, 1 μL of random 6 mers, and 13 μL of DEPC
water, and then incubated at 37°C for 15 min followed
by 85°C for 5 s to inactivate reverse transcriptase. The
cDNA was then used as the template to amplify the tar-
get genes using real-time PCR in a 20 μL system con-
taining 2 μL of cDNA, 10 μL of 2 ×SYBR Premix, 0.4 μL
of Ex Taq, 0.4 μL of forward primer, 0.4 μL of reverse
primer, 0.4 μL of 50× ROX reference dye II, and 6.8 μL
of dH2O under the following conditions: 95°C for 30 s,
followed by 40 cycles at 95°C for 5 s, 55°C for 30 s, and
72°C for 30 s. The primers used for the ATGL amplifica-
tion included the forward primer, 5-AACACCAGCATCC
AGTTCAA-3 and reverse primer, 5-GGTTCAGTAGG
CCATTCCTC-3; for HSL, the primers were: the forward
primer, 5-GGCTCACAGTTACCATCTCACC-3, and the
reverse primer, 5-GAGTACCTTGCTGTCCTGTCC-3.
Primers used for beta-actin amplification were forward, 5-
CATCCGTAAAGACCTCTATGCCAAC-3 and reverse
5-ATGGAGCCACCGATCCACA-3. Relative expression
levels of ATGL and HSL to beta-actin were calculated
as 2
–ΔΔCT.
Western blot analysis
The liver tissues were lysed in RIPA buffer and the protein
concentration was determined using the BCA kit. Cell
membrane or cytoplasmic extracts for the detection of
p47phox (membrane) or FOXO1 (cytoplasm) were pre-
pared by using the appropriate kits (Beyotime, China).
Equal amounts of protein were separated by 10% SDS-
PAGE and transferred to nitrocellulose membrane. The
membranes were blocked in 5% non-fat milk in PBS
and incubated with primary antibodies (1:1000 dilution)
against related proteins overnight at 4°C, followed by incu-
bation with HRP-labeled goat anti-rabbit secondary anti-
body (1:5000) at room temperature for 1 h. The immune
complex was detected with an enhanced chemilumines-
cence system, were exposed to X-ray film, and analyzed.
GAPDH was used as the loading control.
Statistical analysis
Data are expressed as the mean ±S.D. Statistical analysis
was performed using SPSS 11.0 statistical software. Differ-
ences among groups were compared by means of one-way
ANOVA followed by the LSD test to determined signifi-
cance in groups. P values <0.05 were considered statisti-
cally significant.
Results
Res supplementation reduces the body weight and liver
index
During the experimental period, daily food intake of the
KKAy mice was found to be constantly higher than that
of C57BL/6 J mice (P <0.05), while there was no signifi-
cant difference among the three groups (Figure 1A). As
shown in Figure 1B-D, body weight and liver index were
higher in comparison to C57BL/6 J mice, but the change
was reversed in the high Res treatment group.
Dietary Res treatment regulates lipid metabolism and
oxidative activation of KKAy mice
As shown in Figure 2A-D, serum levels of TG, TC, and
LDL-C in KKAy mice were higher than those in C57BL/
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or P <0.01). Compared with non-treated KKAy mice,
the serum level of TG was significantly decreased in the
high Res treatment group (P <0 . 0 1) a n d th e H DL -C
level was increased in both the high and low Res
dietary groups (P <0.05 or P <0 . 0 1) , bu t th e T C a n d
LDL-C levels were not significantly different. As shown
in Figure 2E-G, serum levels of FFA and MDA in KKAy
mice were higher than those in C57BL/6 J mice, while
the SOD level was decreased (P <0.05 o r P < 0.01). In
contrast to non-treated KKAy mice, FFA and MDA
levels in the Res treatment group were significantly de-
creased, while the SOD level was increased (P <0.05 or
P < 0.01).
Dietary Res treatment inhibits the liver oxidative stress
We explored the oxidative regulation effect of Res in
liver tissues. As shown in Figure 3A-E, after the 12-wk
study period, the ROS level was obviously decreased by
dietary Res intervention. The MDA level also trended
downward, but no significant difference was found. In
addition, levels of glutathione (GSH), glutathione perox-
idase (GPx), and SOD increased in our study (P <0.05 or
P <0.01).
Dietary treatment with Res decreases p47phox
(cell membrane) and gp91phox expression
The protein levels of oxidative stress related proteins
were detected by Western blot. As shown in Figure 3F
and G, gp91phox protein levels were significantly increased
in KKAy mice compared with C57BL/6 J (P<0.0 1.Com-
pared with non-treated KKAy mice, p47phox (cell mem-
brane) and gp91phox protein were evidently decreased in
KKAy mice treated with the Res diet (P<0.01). The results
suggest the anti-oxidation level of KKAy mouse liver tissue
can be improved by Res treatment.
Dietary Res treatment reduced hepatic steatosis
We next examined the liver morphological alterations,
the degree of hepatic steatosis, and liver TG and TC
levels. Grossly, we found that Res treatment significantly
attenuated the fat infiltration in the liver as shown in
Figure 4A and B. Fresh liver tissue was bright red with
smooth surfaces and sharp edges in C57BL/6 J mice, but
in non-treated KKAy mice, the liver tissue was yellow and
swelling, with granular surfaces and blunt edges. Examin-
ation of frozen sections of liver tissue demonstrated
marked microvesicular steatosis and the degree of hepatic
steatosis was significantly alleviated by the dietary intake
Figure 1 Effect of dietary Res treatment on animal characteristics. (A) Average daily food intake of each mouse at 1, 4, 6, 9, and
12 weeks. (B) Body weight (BW) was measured weekly throughout the study. (C) After the Res intervention, mice were sacrificed
under anesthesia and the liver tissues were removed and weighed. (D) The liver index (%), which is equal to the liver weight/body
weight*100%. Data are shown as the mean ± S.D.
#P <0.05 and
##P < 0.01 compared with C57BL/6 J mice.
*P <0 . 0 5v s .t h ec o n t r o lg r o u p
of KKAy mice, n =10.
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sis (Figure 4B). In parallel with the histological findings,
Oil Red O quantitative analysis revealed that the fat de-
posits were markedly decreased by Res treatment (P< 0.01)
(Figure 4C). Furthermore, as shown in Figure 4D and E,
the liver TG level was reduced in Res-treated mice when
compared with non-treated KKAy mice, whereas there
was an insignificant change in TC level.
Up-regulation of p-HSL, HSL and ATGL by dietary Res
treatment in KKAy mice
Real-time PCR was carried out to detect the mRNA levels
of HSL and ATGL after a 12-w study period. As shown in
Figure 5A and B, HSL and ATGL mRNA levels were sig-
nificantly decreased in KKAy mice compared with C57BL/
6 J, and this decrease was evidently reversed by high Res
dietary treatment (P<0.01). In agreement with PCR find-
ings, Western blot analysis showed that ATGL and HSL
p r o t e i n sw e r eu p - r e g u l a t e di nK K A ym i c et r e a t e dw i t h
the high Res diet. Additionally, p-HSL protein was highly
expressed in both the low and high Res treatment groups
(P<0.01), as shown in Figure 5C and D.
Dietary treatment with Res increases Sirt1, p-AMPKα,
p-FOXO1 and FOXO1 (cytoplasm) expression
Finally, we studied the possible underlying regulation mech-
anisms of Res. As shown in Figure 6, down-regulation of
Sirt1, p-AMPK α, p-FOXO1 and FOXO1 (cytoplasm) in
KKAy mice was reversed by Res treatment compared with
C57BL/6 J mice. However, there was no effect on AMPK
α or total FOXO1 protein expression.
Discussion
Our study proves that Res can attenuate the effects in
KKAy mice from oxidative stress and lipid metabolic
disorders. Prior to Res intervention, KKAy mice present
with weight gain and increases in TG, TC, and LDL-C
levels compared to C57BL/6 J mice, moreover, after
Figure 2 Effects of dietary Res treatment on serum lipid levels and oxidative stress conditions. (A, B, C, D) Serum levels of TG, TC, LDL-C
and HDL-C, which represent serum lipid levels were measured before the Res treatment and after a 12-wk study period. (E, F, G). Serum levels of
FFA, SOD and MDA representing oxidative stress conditions were measured as well. Data are shown as the mean±S.D.
#P<0.05 and
##P< 0.01
vs. C57BL/6 J.
*P<0.05 and
**P<0.01 vs. KKAy control, n=10.
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dative stress and metabolic disorders in liver, leading to
the unfavorable decreases of liver enzymes such as GPx,
which is consistent with previous study supporting these
mice as proper animal model for investigation of lipid
metabolic disorders [18]. In our study, we investigated
the effect of Res on lipid metabolism via dietary Res
treatment. KKAy mice presented effective weight loss by
Res dietary treatment, most likely due to inhibition of
lipogenesis and/or lipid mobilization. Meanwhile, Res
has anti-hyperlipidemic effects, as serum levels of TG
were significantly decreased and HDL-C levels increased
in the Res-treated groups, which may be the effect of
improving the blood circulation and decreasing fat de-
position via the inhibition of platelet aggregation [19].
In addition, Res-treated KKAy mice had decreased liver
TG contents and lighter hepatosteatosis, accompanied by
effective attenuation of oxidative stress in the liver. These
anti-oxidation effects of Res were associated with higher
GSH, GPx, and SOD levels in the livers of treated animals.
Excessive oxidative stress plays an important role in the
pathology of hepatic steatosis. Owing to its potent antioxi-
dant effects, Res may be a potential therapeutic modality
for NAFLD.
Generally, lipid and metabolic disorders are very likely
to cause oxidant-antioxidant imbalances in the liver, where
high levels of fatty acids provide the material basis for oxi-
dative stress. Oxidative stress, due to the increased pro-
duction of reactive oxygen species (ROS) and decreased
antioxidant defense, was observed in both human and ex-
perimental models of steatohepatitis and appeared to be a
key factor in the progression of NAFLD [20,21]. Excess
levels of FFAs induced high levels of β-oxidation, and the
production of ROS decreased antioxidant defenses at a
Figure 3 Effects and mechanisms of dietary Res treatment on liver oxidative activation. (A, B, C, D, E). Hepatic levels of ROS, GSH, GPx,
SOD and MDA were measured after a 12-wk study period. (F) Expression of p47phox (cell membrane), gp91phox and GAPDH in liver tissues in
each group determined by Western blotting after intervention, each blot stands for at least three independent samples. (G) Quantitative analysis
of expression levels, which were normalized for GAPDH. Data are shown as the mean±S .D.
#P<0.05 and
##P<0.01 vs. C57BL/6 J.
*P< 0.05 and
**P<0.01 vs. KKAy control, n= 10.
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the induction of necrosis [22]. Thus, the increased oxida-
tive stress could lead to a greater risk for the development
of NASH from simple steatosis. Expressions of p47phox
and gp91phox have been found to increase in obese rats
and be partly responsible for excessive oxidation [23]. Res
appears to have a protective anti-oxidation effect through
free radical scavenging [24]. Res has been found to be able
to attenuate oxidative-induced DNA damage in human
lymphocytes via increasing levels of GSH and modulating
antioxidant enzymes (GPx, GR and GST) [25]. In our study,
down-regulation of p47phox and gp91phox, increased pro-
d u c t i o no fG S H ,G P x ,S O D ,a n dd e c r e a s e ds e r u mM D A
after Res treatment illustrate that Res has anti-oxidative
effects, and thus ameliorates hepatocyte damage and stea-
tosis. Moreover, we observed Res eventually reduced ele-
vated serum FFA in KKAy mice, which may be due to the
fact that Res intervention inhibited FFA synthesis, or
enhanced FFA oxidation. Given that FFA level represents
as important marker to evaluate metabolic disorder, the
amelioration of Res on serum FFA pool would be of great
significance.
As the hepatic steatosis is caused by increased lipo-
genesis and decreased lipolysis, we assumed that Res was
able to reduce hepatic fat deposition via ATGL and HSL
dependent lipolysis. HSL, the rate-limiting enzyme of
intracellular TG hydrolysis, is a major determinant of fatty
acid mobilization in adipose tissue as well as other tissues.
In our research, HSL mRNA and protein levels were up-
regulated in the Res-treated group. Furthermore, p-HSL
protein was highly expressed in both the low and high
Res-treated groups. These results show that Res treatment
increases HSL expression at both the mRNA and protein
levels, and enhances its lipolysis activity via phosphoryl-
ation. ATGL, an essential lipase in many cell types, spe-
cifically hydrolyses long-chain fatty acid TGs and plays an
important role in lipolysis. Haemmerle G et al. reported
that genetic inactivation of ATGL in mice increased
Figure 4 Effects of dietary Res supplementation on hepatic steatosis in KKAy mice. (A) Gross specimens of livers from mice in each group
are shown. (B) Liver biopsy evaluation. Frozen sections of liver tissue were produced, the fat was stained with Oil Red O, and the nuclei were
stained with hematoxylin. The original magnification was ×200. (C) The degree of hepatic steatosis of the mice in the different groups by Oil Red
O quantitative analysis. (D, E) Hepatic levels of TG and TC in mice were measured. Data are shown as the mean±S.D.
##P< 0.01vs. C57BL/6 J.
*P< 0.05 and
**P< 0.01 vs. KKAy control. n= 10.
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multiple tissues. ATGL-deficient mice accumulated large
amounts of lipids in the liver, causing steatosis [26].
Atgl−/−hepatocytes exhibit defects in fatty acid me-
tabolism and are steatotic [27]. Additionally, we have con-
firmed that ATGL expression was up-regulated after Res
treatment in our study. Taken together, we showed that
hepatic HSL and ATGL expressions were increased in
Res-treated mice, and hepatic overexpression of HSL or
ATGL reduces liver TG mass and ameliorates steatosis in
KKAy mice. Based on previous reports and our findings, it
is speculated that Res may promote lipolysis and amelior-
ate hepatic steatosis by activating HSL and ATGL.
Res has been reported to increase mitochondrial function
by activating Sirt1 and extending the lifespan in multiple
model organisms [28]. However, the exact mechanism of
Res as direct Sirt1 activator has been challenged in previous
studies. Beher et al. [29] reported that Res could increase
Sirt1 activity in fluorophore-tagged substrates but not the
corresponding nontagged peptides in vitro. More recently,
Hubbard et al. [30] argued that sirtuin-activating com-
pounds (STACs, resveratrol including) directly activate
Sirt1 through an allosteric mechanism, moreover, the
metabolic effects of STACs are blocked in cells reconsti-
tuted with inactive Sirt1, suggesting Sirt1 directly mediates
STACs regulation in vivo. Despite of these inconsist-
ent mechanistic investigations, Sirt1 was appeared to
be involved in regulating energy homeostasis, food in-
take, body weight and substance metabolism [31]. Loss
or reductions of Sirt1 activity may be associated with
metabolic syndrome. Benefits of Sirt1 overexpression con-
sisted of better glucose tolerance, as well as protection
against hepatic steatosis [32]. Members of the FOXO fam-
ily of transcription factors regulate the expression of
numerous genes involved in the cell cycle, apoptosis,
differentiation, development, DNA repair, and the cellular
response to oxidative stress [33]. FOXO1 is regulated by
post-translational modifications such as ubiquitination,
phosphorylation, acetylation, etc. FoxO factors are consid-
ered to be downstream targets of the protein kinase Akt,
which phosphorylates them and leaves them transcrip-
tionally inactive by resulting in their nuclear exclusion and
possibly subsequent proteasomal degradation [34]. How-
ever, the exact mechanism of the protective role of Res
was largely unknown. In our study, increased expression
of Sirt1 protein after the Res diet suggested that Res-
induced Sirt1 activation may reduce steatosis, although
mechanistically how Res activated Sirt1 remained unclear.
Furthermore, down-regulation of Sirt1 and p-FOXO1 in
KKAy mice were reversed by Res treatment, so we pro-
posed that the Sirt1-FOXO1 pathway may be involved in
resveratrol-mediated amelioration of oxidative stress. In
detail, Sirt1 may increase Akt phosphorylation, which was
reported to be activated after Res intervention in KKAy
Figure 5 Effects of dietary Res treatment on protein expressions of fat metabolism in liver tissues. (A, B) HSL and ATGL mRNAs in liver
tissues were measured by real-time PCR, and beta-actin mRNA was used as referred gene. (C) Protein expression of p-HSL, HSL and ATGL in liver
tissues in each group were determined by Western blotting, each blot stands for at least three independent samples. (D) Quantitative analysis of
protein expression levels, which was normalized for GAPDH. Data are shown as the mean±S.D.
##P<0.01 vs. C57BL/6 J.
**P<0.01 vs. KKAy
control, n=10.
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the nucleus to the cytoplasm, consequently, liver gluco-
neogenesis was inhibited, and lipid metabolic disorder and
oxidative activation were attenuated.
AMP-activated protein kinase (AMPK), an evolution-
arily conserved serine/threonine protein kinase, is a het-
erotrimeric complex comprised of a catalytic subunit and
two regulatory subunits. The primary mechanism respon-
sible for AMPK activation involves phosphorylation of
AMPK at the Thr172 residue located within the activation
loop of the alpha subunit [35]. HMG CoA reductase and
Acetyl CoA carboxylase (ACC) are the key enzymes in
cholesterol and fatty acid synthesis, respectively, also well
as being characterized as downstream targets of AMPK.
Studies have determined that the activation of AMPK
could inhibit cholesterol and fatty acid synthesis via phos-
phorylation of the two enzymes [36]. LKB1 is a serine-
threonine protein kinase that phosphorylates and acti-
vates AMPK. Sirt1 affects downstream targets of LKB1.
Thus, its overexpression increased AMPK and acetyl-
CoA carboxylase phosphorylation, and conversely, RNA
interference-mediated Sirt1 knockdown reduced AMPK
phosphorylation [37]. However, recently Park et al. [38]
reported that Res could elevate cAMP level and sequen-
tially activate AMPK and Sirt1, indicating AMPK could be
the upstream of Sirt1. Our results have revealed that Res
may reduce steatosis via enhanced Sirt1 expression and
increased AMPK phosphorylation. All of these findings
suggest that there is correlation between Sirt1 and AMPK,
but the exact regulating mechanism is uncertain.
In conclusion, we suggest that Res may attenuate fat
deposition and ameliorate oxidative stress in a KKAy
mouse model, most likely via up-regulation of Sirt1 and
AMPK. Due to its protective role against hepatic steato-
sis, Res may be applied for the treatment of NAFLD.
Further studies are warranted to determine whether Res
may be recommended as an effective strategy for pre-
venting and/or treating NAFLD in humans.
Figure 6 Effects of dietary Res treatment on Sirt1, p-AMPK,AMPK, p-FOXO1, FOXO1 protein expressions in liver tissues. (A) Sirt1, p-AMPK,
AMPK, p-FOXO1, and FOXO1 protein expressions were measured by Western blotting, each blot stands for at least three independent samples.
(B, C, D) Quantitative analysis of expression levels, which was normalized for GAPDH. Data are shown as the mean±S.D.
##P<0.01 vs. C57BL/6 J.
**P<0.01 vs. KKAy control, n=10 .
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